Market Overview

Aerie Pharmaceuticals Appoints David W. Gryska to the Company's Board of Directors

Share:

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with open-angle
glaucoma, retina diseases and other diseases of the eye, today
announced that David W. Gryska has been appointed to the Company's Board
of Directors and will also be a member of the Audit Committee of the
Board. David brings extensive executive level healthcare-focused and
financial leadership experience from large global biopharmaceutical
firms.

Mr. Gryska recently announced his planned retirement at the end of 2018
as the Chief Financial Officer and Executive Vice President of Incyte
Corp., and is currently on the boards of Seattle Genetics, Inc. and PDL
BioPharma, Inc. Previously, he held the position of President, CEO, COO
and Director at Myrexis, Inc., Chief Financial Officer and Senior Vice
President at Celgene Corp., and Chief Financial Officer and Senior Vice
President at Scios, Inc. Mr. Gryska has spent over 20 years as a senior
executive at life science and biotechnology companies with extensive
experience relating to financings, acquisitions, global expansion and
strategic transactions. Mr. Gryska was previously a member of Aerie's
Board of Directors from May of 2012 through May of 2015.

"We are pleased to welcome Dave back to the Company's Board. He brings a
tremendous amount of experience and strategic vision as Aerie moves
forward into our most exciting period, from our successful Rhopressa®
launch, potential Roclatan™ regulatory approval, our global expansion
and pursuit of new opportunities in our pipeline, including for retina
diseases. He will be a highly valued contributor as we continue to build
a major ophthalmic pharmaceutical company," said Vicente Anido, Jr.,
Ph.D., Chairman and Chief Executive Officer at Aerie.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with open-angle glaucoma, retina diseases and
other diseases of the eye. Aerie's first product, Rhopressa® (netarsudil
ophthalmic solution) 0.02%, a once-daily eyedrop approved by the U.S.
Food and Drug Administration (FDA) for the reduction of elevated
intraocular pressure (IOP) in patients with open-angle glaucoma or
ocular hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse
reactions were conjunctival hyperemia, cornea verticillata, instillation
site pain, and conjunctival hemorrhage. More information about Rhopressa®,
including the full product label, is available at www.rhopressa.com.
Aerie's advanced-stage product candidate,
Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a
fixed-dose combination of Rhopressa® and the
widely-prescribed PGA (prostaglandin analog) latanoprost, achieved its
3-month primary efficacy endpoint in two Phase 3 registration trials,
Mercury 1 and Mercury 2, and also showed safety and efficacy throughout
12 months in Mercury 1. Aerie submitted the Roclatan™ New Drug
Application (NDA) in May 2018 and, in July 2018, the FDA set the PDUFA
(Prescription Drug User Fee Act) goal date for the completion of the
FDA's review of the Roclatan™ NDA for March 14, 2019. Aerie continues to
focus on global expansion and the development of additional product
candidates and technologies in ophthalmology, including for wet
age-related macular degeneration and diabetic macular edema. More
information is available at www.aeriepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should," "exploring," "pursuing", "opportunities" or other
words that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: our
expectations regarding the commercial launch and sales of Rhopressa®
and Roclatan™ and any future product candidates, if approved; our
commercialization, marketing, manufacturing and supply management
capabilities and strategies; third-party payer coverage and
reimbursement of Rhopressa® and Roclatan™ and any future
product candidates, if approved; the glaucoma patient market size and
the rate and degree of market adoption of Rhopressa® and
Roclatan™ and any future product candidates, if approved, by eye-care
professionals and patients; the timing cost or other aspects of the
commercial launch of Rhopressa® and Roclatan™ and any future
product candidates, if approved; the success, timing and cost of our
ongoing and anticipated preclinical studies and clinical trials for
Rhopressa®, with respect to regulatory approval outside the
United States, and Roclatan™ and any future product candidates,
including statements regarding the timing of initiation and completion
of the studies and trials; our expectations regarding the effectiveness
of Rhopressa®, Roclatan™ and any future product candidates
and results of our clinical trials and any potential preclinical
studies; the timing of and our ability to request, obtain and maintain
FDA or other regulatory authority approval of, or other action with
respect to, as applicable, Rhopressa®, Roclatan™ and any
future product candidates in the United States, Canada, Europe, Japan
and elsewhere, including the expected timing of, and regulatory and/or
other review of, filings for, as applicable, Rhopressa®,
Roclatan™ and any future product candidates; the potential advantages of
Rhopressa®, Roclatan™ and any future product candidates; our
plans to pursue development of additional product candidates and
technologies in ophthalmology, including development of Rhopressa® and
Roclatan™ for additional indications, our preclinical retina programs
and other therapeutic opportunities; our plans to explore possible uses
of our existing proprietary compounds beyond glaucoma and ophthalmology;
our ability to protect our proprietary technology and enforce our
intellectual property rights; and our expectations regarding
collaborations, licensing, acquisitions and strategic operations,
including our ability to in-license or acquire additional ophthalmic
products, product candidates or technologies. By their nature,
forward-looking statements involve risks and uncertainties because they
relate to events, competitive dynamics, industry change and other
factors beyond our control, and depend on regulatory approvals and
economic and other environmental circumstances that may or may not occur
in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading "Risk Factors" in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). In particular, FDA
approval of Rhopressa® does not constitute FDA approval of
Roclatan™, and there can be no assurance that we will receive FDA
approval for Roclatan™ or for any future product candidates. FDA
approval of Rhopressa® also does not constitute regulatory
approval of Rhopressa® in jurisdictions outside the United
States, and there can be no assurance that Rhopressa® will
obtain regulatory approval in other jurisdictions. Our receipt of a
Prescription Drug User Fee Act (PDUFA) goal date notification for
Roclatan™ does not constitute FDA approval of the Roclatan™ New Drug
Application (NDA), and there can be no assurance that the FDA will
complete its review by the PDUFA goal date of March 14, 2019, that the
FDA will not require changes or additional data that must be made or
received before it will approve the NDA, if ever, or that the FDA will
approve the NDA. Forward-looking statements are not guarantees of future
performance and our actual results of operations, financial condition
and liquidity, and the development of the industry in which we operate
may differ materially from the forward-looking statements contained in
this press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We assume
no obligation to update our forward-looking statements whether as a
result of new information, future events or otherwise, after the date of
this press release.

View Comments and Join the Discussion!